Sagent Pharmaceuticals Inc (SGNT) 27.85 $SGNT
Ryanair Holdings (RYAAY) Jumps: Stock Adds 7.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 8:11AM CST
Ryanair Holdings plc (RYAAY) was a big mover last session, as the company saw its shares rise over 7% on the day.
LCI: 43.58 (-0.46), RYAAY: 68.30 (-0.35), SGNT: 27.85 (-0.65), IG: 8.78 (+0.12)
Otonomy (OTIC) Jumps: Stock Adds 5.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 8:11AM CST
Otonomy, Inc. (OTIC) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
LCI: 43.58 (-0.46), SGNT: 27.85 (-0.65), IG: 8.78 (+0.12), OTIC: 36.72 (+2.60)
Sagent (SGNT) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 7:56AM CST
Sagent (SGNT) Sees Hammer Chart Pattern: Time to Buy?
SGNT: 27.85 (-0.65)
Sagent Chairman and CEO Jeff Yordon Inducted Into the UIC Chicago Area Entrepreneurship Hall of Fame
GlobeNewswire - Fri Nov 07, 8:35AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) ("Sagent"
, a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that Jeff Yordon, the company's Chairman and Chief Executive Officer, has been inducted into the UIC Chicago Area Entrepreneurship Hall of Fame.
SGNT: 27.85 (-0.65)
Sagent Pharmaceuticals' (SGNT) CEO Jeff Yordon on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:09PM CST
SGNT: 27.85 (-0.65)
Sagent Pharmaceuticals (SGNT) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 04, 7:55AM CST
SGNT: 27.85 (-0.65)
Sagent Pharmaceuticals beats by $0.12, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 6:06AM CST
SGNT: 27.85 (-0.65)
Sagent Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced financial results for the quarter ended September 30, 2014.
SGNT: 27.85 (-0.65)
Sagent Pharma reports November 4
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 3:07PM CDT
SGNT: 27.85 (-0.65)
Sagent Pharmaceuticals Sets Date and Time for Release of Third Quarter 2014 Financial Results
GlobeNewswire - Fri Oct 24, 3:00PM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will release financial results for the 2014 third quarter pre-market on Tuesday, November 4, 2014 and will host a teleconference and webcast at 9 a.m. ET to review the results.
SGNT: 27.85 (-0.65)
How Sagent Pharmaceuticals (SGNT) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:41AM CDT
Sagent Pharmaceuticals belongs to the Med-drugs industry, is a decent pick as it witnessed solid earnings estimate revision activity with a favorable Zacks Industry Rank.
SGNT: 27.85 (-0.65)
3 Stocks Spiking on Big Volume
at The Street - Tue Oct 14, 8:39AM CDT
Keep these stocks rising on unusual volume on your trading radar.
NJR: 58.72 (-1.20), FFIV: 130.54 (-1.84), SGNT: 27.85 (-0.65)
MEI Pharma (MEIP) Soars: Stock Adds 5.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 7:51AM CDT
MEI Pharma, Inc. (MEIP) was a big mover last session, as its shares rose over 5% on the day.
ACRX: 6.40 (unch), SGNT: 27.85 (-0.65), HPTX: 21.89 (+0.02), MEIP: 4.20 (unch)
Auxilium Pharmaceuticals (AUXL) Jumps: Stock Rises 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 8:39AM CDT
Auxilium Pharmaceuticals Inc. (AUXL) was a big mover last session, as the company shares rose a little over 9% on the day.
SGNT: 27.85 (-0.65), HPTX: 21.89 (+0.02)
Surging Earnings Estimates Signal Good News for Sagent Pharmaceuticals (SGNT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 7:41AM CDT
Sagent Pharmaceuticals could be a solid choice for investors, as it witnessed solid activity on the earnings estimate revision front and also has a favorable Zacks Rank.
SGNT: 27.85 (-0.65)
Strong And Under The Radar: Sagent Pharmaceuticals (SGNT)
at The Street - Wed Oct 08, 1:16PM CDT
Trade-Ideas LLC identified Sagent Pharmaceuticals (SGNT) as a strong and under the radar candidate
SGNT: 27.85 (-0.65)
Zogenix (ZGNX) Shows Strength: Stock Adds 11.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:39AM CDT
Zogenix, Inc. (ZGNX) was a big mover last session, as the company shares rose over 11% on the day.
LCI: 43.58 (-0.46), ZGNX: 1.15 (-0.02), SGNT: 27.85 (-0.65), HPTX: 21.89 (+0.02)
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 7:51AM CDT
BioCryst Pharmaceuticals, Inc. (BCRX) was a big mover last session, as the company shares rose over 12% on the day.
LCI: 43.58 (-0.46), BCRX: 10.06 (+0.02), SGNT: 27.85 (-0.65), HPTX: 21.89 (+0.02)
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Three Lots of Ketorolac Tromethamine Injection, USP, 30mg/mL Due to Labeling the Product With the Incorrect Expiration Date
GlobeNewswire - Fri Oct 03, 11:02AM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the voluntary nationwide recall of three lots of Ketorolac Tromethamine Injection, USP, 30mg/mL single-dose vials (NDC numbers 25021-701-01 and 25021-701-02) manufactured by Cadila Healthcare Limited and distributed by Sagent. Sagent has initiated this voluntary recall of Ketorolac Tromethamine Injection, USP, 30mg/mL to the user level due to labeling the product with the incorrect expiration date. The labeled expiration date is longer than the known stability of the product.
SGNT: 27.85 (-0.65)
Tourette Syndrome Market Analysis 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fj7985/tourette_syndrome) has announced the addition of the "Tourette Syndrome Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Tourette Syndrome- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Janssen Pharmaceuticals, Inc. - Sagent Pharmaceuticals, Inc. - Teva Pharmaceuticals USA, Inc. For more information visit http://www.researchandmarkets.com/research/fj...e_syndrome
SGNT: 27.85 (-0.65)
Ryanair Holdings (RYAAY) Jumps: Stock Adds 7.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 8:11AM CST
Ryanair Holdings plc (RYAAY) was a big mover last session, as the company saw its shares rise over 7% on the day.
LCI: 43.58 (-0.46), RYAAY: 68.30 (-0.35), SGNT: 27.85 (-0.65), IG: 8.78 (+0.12)
Otonomy (OTIC) Jumps: Stock Adds 5.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 8:11AM CST
Otonomy, Inc. (OTIC) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
LCI: 43.58 (-0.46), SGNT: 27.85 (-0.65), IG: 8.78 (+0.12), OTIC: 36.72 (+2.60)
Sagent (SGNT) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 7:56AM CST
Sagent (SGNT) Sees Hammer Chart Pattern: Time to Buy?
SGNT: 27.85 (-0.65)
Sagent Chairman and CEO Jeff Yordon Inducted Into the UIC Chicago Area Entrepreneurship Hall of Fame
GlobeNewswire - Fri Nov 07, 8:35AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) ("Sagent"
, a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that Jeff Yordon, the company's Chairman and Chief Executive Officer, has been inducted into the UIC Chicago Area Entrepreneurship Hall of Fame. SGNT: 27.85 (-0.65)
Sagent Pharmaceuticals' (SGNT) CEO Jeff Yordon on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:09PM CST
SGNT: 27.85 (-0.65)
Sagent Pharmaceuticals (SGNT) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 04, 7:55AM CST
SGNT: 27.85 (-0.65)
Sagent Pharmaceuticals beats by $0.12, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 6:06AM CST
SGNT: 27.85 (-0.65)
Sagent Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced financial results for the quarter ended September 30, 2014.
SGNT: 27.85 (-0.65)
Sagent Pharma reports November 4
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 3:07PM CDT
SGNT: 27.85 (-0.65)
Sagent Pharmaceuticals Sets Date and Time for Release of Third Quarter 2014 Financial Results
GlobeNewswire - Fri Oct 24, 3:00PM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will release financial results for the 2014 third quarter pre-market on Tuesday, November 4, 2014 and will host a teleconference and webcast at 9 a.m. ET to review the results.
SGNT: 27.85 (-0.65)
How Sagent Pharmaceuticals (SGNT) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:41AM CDT
Sagent Pharmaceuticals belongs to the Med-drugs industry, is a decent pick as it witnessed solid earnings estimate revision activity with a favorable Zacks Industry Rank.
SGNT: 27.85 (-0.65)
3 Stocks Spiking on Big Volume
at The Street - Tue Oct 14, 8:39AM CDT
Keep these stocks rising on unusual volume on your trading radar.
NJR: 58.72 (-1.20), FFIV: 130.54 (-1.84), SGNT: 27.85 (-0.65)
MEI Pharma (MEIP) Soars: Stock Adds 5.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 7:51AM CDT
MEI Pharma, Inc. (MEIP) was a big mover last session, as its shares rose over 5% on the day.
ACRX: 6.40 (unch), SGNT: 27.85 (-0.65), HPTX: 21.89 (+0.02), MEIP: 4.20 (unch)
Auxilium Pharmaceuticals (AUXL) Jumps: Stock Rises 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 8:39AM CDT
Auxilium Pharmaceuticals Inc. (AUXL) was a big mover last session, as the company shares rose a little over 9% on the day.
SGNT: 27.85 (-0.65), HPTX: 21.89 (+0.02)
Surging Earnings Estimates Signal Good News for Sagent Pharmaceuticals (SGNT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 7:41AM CDT
Sagent Pharmaceuticals could be a solid choice for investors, as it witnessed solid activity on the earnings estimate revision front and also has a favorable Zacks Rank.
SGNT: 27.85 (-0.65)
Strong And Under The Radar: Sagent Pharmaceuticals (SGNT)
at The Street - Wed Oct 08, 1:16PM CDT
Trade-Ideas LLC identified Sagent Pharmaceuticals (SGNT) as a strong and under the radar candidate
SGNT: 27.85 (-0.65)
Zogenix (ZGNX) Shows Strength: Stock Adds 11.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:39AM CDT
Zogenix, Inc. (ZGNX) was a big mover last session, as the company shares rose over 11% on the day.
LCI: 43.58 (-0.46), ZGNX: 1.15 (-0.02), SGNT: 27.85 (-0.65), HPTX: 21.89 (+0.02)
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 7:51AM CDT
BioCryst Pharmaceuticals, Inc. (BCRX) was a big mover last session, as the company shares rose over 12% on the day.
LCI: 43.58 (-0.46), BCRX: 10.06 (+0.02), SGNT: 27.85 (-0.65), HPTX: 21.89 (+0.02)
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Three Lots of Ketorolac Tromethamine Injection, USP, 30mg/mL Due to Labeling the Product With the Incorrect Expiration Date
GlobeNewswire - Fri Oct 03, 11:02AM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the voluntary nationwide recall of three lots of Ketorolac Tromethamine Injection, USP, 30mg/mL single-dose vials (NDC numbers 25021-701-01 and 25021-701-02) manufactured by Cadila Healthcare Limited and distributed by Sagent. Sagent has initiated this voluntary recall of Ketorolac Tromethamine Injection, USP, 30mg/mL to the user level due to labeling the product with the incorrect expiration date. The labeled expiration date is longer than the known stability of the product.
SGNT: 27.85 (-0.65)
Tourette Syndrome Market Analysis 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fj7985/tourette_syndrome) has announced the addition of the "Tourette Syndrome Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Tourette Syndrome- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Janssen Pharmaceuticals, Inc. - Sagent Pharmaceuticals, Inc. - Teva Pharmaceuticals USA, Inc. For more information visit http://www.researchandmarkets.com/research/fj...e_syndrome
SGNT: 27.85 (-0.65)
